Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sol-Gel Technologies Ltd. (SLGL)
USD77.29
+1.90 (+2.52%)
IL NASDAQ Healthcare Biotechnology
Address
7 Golda Meir Street 7403650
Ness Ziona, IL
Ness Ziona, IL
CEO
Moshe Arkin
Website
sol-gel.com
IPO
2018-02-01
CIK 1684693 ISIN IL0011417206
Description
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD77.29
+1.90 (+2.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
38.6K
Beta
1.13
Float Shares
733.2K
Free Float %
26.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.01% | +7.62% | +6.15% | -17.89% | +77.46% | +78.64% | +938.34% | +121.41% | -27.12% | -44.81% | -44.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
77.29
Low
50.00
-35.3%
Consensus
50.00
-35.3%
Median
50.00
-35.3%
High
50.00
-35.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
50.00
-35.3%
|
| All Time | 2 |
35.50
-54.1%
|
Quality scores
Altman Z-Score
13.22
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+68.0% ★ Q1'26: -89.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-479.0% Q1'26: -309.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-6.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-39.2% Q1'26: -3,569.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +2,753.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-90.0% ★ Q1'26: -89.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
129.0K
est: 95.2K (+35.5%)
|
22.90M
est: 23.14M (-1.0%)
|
8.77M
est: 8.30M (+5.7%)
|
31.27M
est: 28.50M (+9.7%)
|
3.88M
est: 5.68M (-31.6%)
|
1.55M
est: 6.56M (-76.3%)
|
11.54M
est: 13.30M (-13.2%)
|
19.39M
est: 25.20M (-23.1%)
|
5.30M
5.30M – 5.30M
-79.0% YoY
|
17.10M
17.10M – 17.10M
+222.6% YoY
|
23.00M
23.00M – 23.00M
+34.5% YoY
|
64.00M
64.00M – 64.00M
+178.3% YoY
|
120.00M
120.00M – 120.00M
+87.5% YoY
|
| EBITDA |
-32.76M
est: -71.9K (-45,491.1%)
|
-25.06M
est: -17.46M (-43.5%)
|
-29.29M
est: -6.26M (-367.8%)
|
3.84M
est: -21.51M (+117.9%)
|
-15.68M
est: -4.29M (-265.8%)
|
-28.96M
est: -4.15M (-598.7%)
|
-10.35M
est: -8.41M (-23.1%)
|
-7.48M
est: -15.93M (+53.0%)
|
-3.35M
-3.35M – -3.35M
+79.0% YoY
|
-10.81M
-10.81M – -10.81M
-222.6% YoY
|
-14.54M
-14.54M – -14.54M
-34.5% YoY
|
-40.45M
-40.45M – -40.45M
-178.3% YoY
|
-75.84M
-75.84M – -75.84M
-87.5% YoY
|
| EBIT |
-33.52M
est: -72.8K (-45,961.8%)
|
-25.95M
est: -17.69M (-46.7%)
|
-30.23M
est: -6.34M (-376.8%)
|
2.96M
est: -21.79M (+113.6%)
|
-16.24M
est: -4.34M (-274.1%)
|
-29.31M
est: -4.22M (-595.1%)
|
-10.58M
est: -8.55M (-23.8%)
|
-7.59M
est: -16.20M (+53.1%)
|
-3.41M
-3.41M – -3.41M
+79.0% YoY
|
-10.99M
-10.99M – -10.99M
-222.6% YoY
|
-14.78M
-14.78M – -14.78M
-34.5% YoY
|
-41.14M
-41.14M – -41.14M
-178.3% YoY
|
-77.13M
-77.13M – -77.13M
-87.5% YoY
|
| Net Income |
-32.20M
est: -496.98M (+93.5%)
|
-24.61M
est: -362.71M (+93.2%)
|
-29.29M
est: -412.99M (+92.9%)
|
3.22M
est: -15.32M (+121.0%)
|
-14.92M
est: -144.86M (+89.7%)
|
-27.24M
est: -1.49M (-1,726.5%)
|
-10.58M
est: -7.80M (-35.6%)
|
-6.13M
est: -2.06M (-197.2%)
|
-31.79M
-31.79M – -31.79M
-1,441.9% YoY
|
-41.01M
-41.01M – -41.01M
-29.0% YoY
|
-41.76M
-41.76M – -41.76M
-1.8% YoY
|
-21.42M
-21.42M – -21.42M
+48.7% YoY
|
13.51M
13.51M – 13.51M
+163.1% YoY
|
| SGA |
5.50M
est: 165.6K (+3,224.7%)
|
8.28M
est: 40.23M (-79.4%)
|
11.09M
est: 14.43M (-23.1%)
|
8.45M
est: 49.57M (-83.0%)
|
7.45M
est: 9.88M (-24.6%)
|
7.37M
est: 10.03M (-26.5%)
|
5.75M
est: 20.34M (-71.7%)
|
4.18M
est: 38.53M (-89.2%)
|
8.10M
8.10M – 8.10M
-79.0% YoY
|
26.15M
26.15M – 26.15M
+222.6% YoY
|
35.17M
35.17M – 35.17M
+34.5% YoY
|
97.87M
97.87M – 97.87M
+178.3% YoY
|
183.50M
183.50M – 183.50M
+87.5% YoY
|
| EPS |
-1.80
est: -17.84 (+89.9%)
|
-1.26
est: -13.02 (+90.3%)
|
-1.30
est: -14.83 (+91.2%)
|
1.40
est: -0.55 (+354.5%)
|
-0.65
est: -5.20 (+87.5%)
|
-1.01
est: -0.54 (-88.7%)
|
-0.38
est: -2.80 (+86.4%)
|
-2.20
est: -0.74 (-197.3%)
|
-11.41
-11.41 – -11.41
-1,441.9% YoY
|
-14.72
-14.72 – -14.72
-29.0% YoY
|
-14.99
-14.99 – -14.99
-1.8% YoY
|
-7.69
-7.69 – -7.69
+48.7% YoY
|
4.85
4.85 – 4.85
+163.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-802.5K
OE per share TTM
-0.03
Owner's Yield
-0.38%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
23.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
99.35M
Insider transactions (90d)
3
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Moshe Arkin | 14.52M | 62.21% | 86.0K | 14.43M | 86.0K | 10.00 | IN | Israel | 2020-04-20 | ↗ |
| 2 | Arkin Dermatology Ltd. | 14.43M | 61.84% | — | 14.43M | — | 10.00 | CO | Israel | 2020-04-20 | ↗ |
| 3 | The Phoenix Holdings Ltd. | 2.57M | 11.13% | — | 2.57M | — | 2.57M | CO | Israel | 2022-02-07 | ↗ |
| 4 | Armistice Capital, LLC | 2.14M | 7.68% | — | 2.14M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 5 | Steven Boyd | 2.14M | 7.68% | — | 2.14M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 6 | Delek Group Ltd. | 2.04M | 10.08% | — | 2.04M | — | 2.04M | CO | Israel | 2019-09-18 | ↗ |
| 7 | Itshak Sharon (Tshuva) | 2.04M | 10.08% | — | 2.04M | — | 2.04M | IN | Israel | 2019-09-18 | ↗ |
| 8 | Migdal Insurance & Financial Holdings Ltd | 1.23M | 5.31% | — | 1.23M | — | — | HC | Israel | 2024-01-31 | ↗ |
| 9 | The Phoenix Holding Ltd. | 1.01M | 5.61% | — | 1.01M | — | 1.01M | CO | Israel | 2018-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
+6 vs prev Q
New positions
9
Closed positions
3
Increased
13
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MENORA MIVTACHIM HOLDINGS LTD. | 7.6K +— (+0.0%) | 320.7K +98.9K (+44.6%) | 0.27% +0.000 pp | 0.00% +0.000 pp | USD29.15 +44.6% | 7 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.50% | 109.9K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
5.0K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+5,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,563 | 64.43 | 100.7K | 490,000 | I | ↗ |
| 2026-05-13 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,937 | 66.87 | 129.5K | 488,437 | I | ↗ |
| 2026-05-12 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,500 | 67.98 | 102.0K | 486,500 | I | ↗ |
| 2026-03-24 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 34,665 | 72.00 | 2.50M | 485,000 | I | ↗ |
| 2026-03-18 | Yosef Itzik | Officer | — | — | Stock Option (right to buy) | 499 | 8.96 | 4.5K | 0 | D | ↗ |
| 2026-03-18 | Toledano Ofer | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 1,461 | D | ↗ |
| 2026-03-18 | Levy-Hacham Ofra | Officer | — | — | Stock Option (right to buy) | 3,568 | 55.66 | 198.6K | 0 | D | ↗ |
| 2026-03-18 | Lerman Hanna | Director | — | — | Stock Option (right to buy) | 2,031 | 55.66 | 113.0K | 0 | D | ↗ |
| 2026-03-18 | Kochan Sharon | Director | — | — | Stock Option (right to buy) | 7,500 | 12.00 | 90.0K | 0 | D | ↗ |
| 2026-03-18 | Gottfried Ran | Director | — | — | Stock Option (right to buy) | 7,500 | 12.00 | 90.0K | 0 | D | ↗ |
| 2026-03-18 | Glezin Michael | Officer | — | — | Stock Option (right to buy) | 5,000 | 8.96 | 44.8K | 0 | D | ↗ |
| 2026-03-18 | Ben-Or Eyal | Officer | — | — | Stock Option (right to buy) | 7,500 | 69.50 | 521.3K | 0 | D | ↗ |
| 2026-03-18 | Arkin Moshe | Director / Officer / 10% Owner | — | — | Ordinary Shares | 0 | 0.00 | — | 1,606,856 | I | ↗ |
| 2026-03-18 | Arkin Itai Gidon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-02-13 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 291 | 63.00 | 18.3K | 450,335 | I | ↗ |
| 2026-02-02 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 100 | 58.00 | 5.8K | 450,044 | I | ↗ |
| 2026-01-27 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 100 | 57.05 | 5.7K | 449,944 | I | ↗ |
| 2026-01-23 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,151 | 55.98 | 64.4K | 449,844 | I | ↗ |
| 2026-01-22 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 2,173 | 56.57 | 122.9K | 448,693 | I | ↗ |
| 2026-01-05 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 198 | 42.98 | 8.5K | 447,331 | I | ↗ |
| 2026-01-02 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 2,394 | 41.92 | 100.3K | 447,133 | I | ↗ |
| 2025-12-31 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 22,497 | 41.99 | 944.7K | 443,739 | I | ↗ |
| 2025-12-30 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 35,169 | 41.99 | 1.48M | 421,242 | I | ↗ |
| 2025-12-29 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 8,638 | 41.85 | 361.5K | 386,073 | I | ↗ |
| 2025-12-26 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,626 | 41.68 | 67.8K | 377,435 | I | ↗ |
| 2025-12-23 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 260 | 41.66 | 10.8K | 375,809 | I | ↗ |
| 2025-12-22 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 1,019 | 41.15 | 41.9K | 375,549 | I | ↗ |
| 2025-12-17 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 2,735 | 40.37 | 110.4K | 374,530 | I | ↗ |
| 2025-12-12 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 87 | 40.00 | 3.5K | 371,795 | I | ↗ |
| 2025-12-08 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 300 | 39.78 | 11.9K | 371,708 | I | ↗ |
| 2025-12-05 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 444 | 39.50 | 17.5K | 371,408 | I | ↗ |
| 2025-12-03 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 2,524 | 37.81 | 95.4K | 370,964 | I | ↗ |
| 2025-12-01 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 4,340 | 37.37 | 162.2K | 368,440 | I | ↗ |
| 2025-11-26 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 943 | 40.00 | 37.7K | 364,100 | I | ↗ |
| 2025-11-24 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 6 | 35.50 | 213.00 | 363,157 | I | ↗ |
| 2025-11-20 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Ordinary Shares, par value NIS 1.00 per share. | 5,784 | 35.83 | 207.2K | 363,151 | I | ↗ |
| 2025-11-13 | Opaleye Management Inc. | 10% Owner | — | — | Ordinary Shares, par value NIS 1.00 per share | 0 | 0.00 | — | 357,367 | I | ↗ |
| 2023-01-07 | Arkin Moshe | Director / Officer / 10% Owner | — | — | Warrants (right to buy) | 200,000 | 58.50 | 11.70M | 0 | I | ↗ |
Executive team
Top executives
EBIT / Employee
-223.3K
Shares Outstanding
2.81M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Glezin | Chief Business Officer | 288.0K | male |
| Itzik Yosef | Chief Operating Officer | 280.0K | — |
| Eyal Ben-Or | Chief Financial Officer | 267.0K | male |
| Moshe Arkin | Chief Executive Officer & Executive Chairman | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLGL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
